Imatinib mesylate in scleroderma-associated diffuse skin fibrosis: a phase II multicentre randomized double-blinded controlled trial

Summary Background Imatinib mesylate is a potent inhibitor of platelet‐derived growth factor and transforming growth factor‐β signalling pathways which may play a role in systemic sclerosis (SSc)‐associated skin changes. Objectives We aimed primarily at assessing the efficacy of imatinib mesylate...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	British journal of dermatology (1951) 2012-11, Vol.167 (5), p.1138-1144
Hauptverfasser:	Prey, S., Ezzedine, K., Doussau, A., Grandoulier, A.-S., Barcat, D., Chatelus, E., Diot, E., Durant, C., Hachulla, E., de Korwin-Krokowski, J.-D., Kostrzewa, E., Quemeneur, T., Paul, C., Schaeverbeke, T., Seneschal, J., Solanilla, A., Sparsa, A., Bouchet, S., Lepreux, S., Mahon, F.-X., Chene, G., Taïeb, A.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Benzamides Biological and medical sciences Dermatology Double-Blind Method Female Fibrosis - drug therapy Humans Imatinib Mesylate Male Medical sciences Middle Aged Piperazines - therapeutic use Platelet-Derived Growth Factor - metabolism Protein Kinase Inhibitors - therapeutic use Pyrimidines - therapeutic use Quality of Life Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis Scleroderma, Diffuse - drug therapy Scleroderma, Diffuse - metabolism Skin - pathology Transforming Growth Factor beta - metabolism Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!